MA47317A - Induction d'immunité protectrice contre des antigènes - Google Patents

Induction d'immunité protectrice contre des antigènes

Info

Publication number
MA47317A
MA47317A MA047317A MA47317A MA47317A MA 47317 A MA47317 A MA 47317A MA 047317 A MA047317 A MA 047317A MA 47317 A MA47317 A MA 47317A MA 47317 A MA47317 A MA 47317A
Authority
MA
Morocco
Prior art keywords
induction
immunity against
protective immunity
against antigens
antigens
Prior art date
Application number
MA047317A
Other languages
English (en)
Inventor
Roy Curtiss Iii
Shifeng Wang
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of MA47317A publication Critical patent/MA47317A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MA047317A 2017-01-23 2018-01-23 Induction d'immunité protectrice contre des antigènes MA47317A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762449228P 2017-01-23 2017-01-23
US201762541293P 2017-08-04 2017-08-04

Publications (1)

Publication Number Publication Date
MA47317A true MA47317A (fr) 2019-11-27

Family

ID=62908819

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047317A MA47317A (fr) 2017-01-23 2018-01-23 Induction d'immunité protectrice contre des antigènes

Country Status (10)

Country Link
US (2) US10988729B2 (fr)
EP (1) EP3571288A4 (fr)
JP (1) JP7121016B2 (fr)
CN (1) CN110462020B (fr)
AU (1) AU2018210554B2 (fr)
BR (1) BR112019015140A2 (fr)
CA (1) CA3050724A1 (fr)
MA (1) MA47317A (fr)
MX (1) MX2019008645A (fr)
WO (1) WO2018136938A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3050724A1 (fr) * 2017-01-23 2018-07-26 University Of Florida Research Foundation, Incorporated Induction d'immunite protectrice contre des antigenes
BR112019015425A2 (pt) * 2017-01-27 2020-05-26 University Of Florida Research Foundation, Incorporated Uma vacina de segurança alimentar para controlar salmonella enterica e reduzir campylobacter em aves domésticas
CN111182920B (zh) 2017-08-04 2023-09-12 佛罗里达大学研究基金公司 针对抗原的保护性免疫的诱导
CA3143498A1 (fr) * 2019-06-19 2020-12-24 Chan Zuckerberg Biohub, Inc. Bacteries concues pour obtenir des lymphocytes t specifiques a un antigene
CN110904140B (zh) * 2019-12-20 2021-05-07 台州职业技术学院 一种蛋白动态表达调控系统及其在莽草酸生产中的应用
CA3170478A1 (fr) * 2020-03-05 2021-09-10 James E. Galen Vecteurs vivants de salmonella typhi modifies pour exprimer des antigenes de proteines cancereuses et leurs procedes d'utilisation
CN111793591B (zh) * 2020-06-22 2022-11-25 南昌大学 一株高效刺激免疫反应的沙门菌突变株及构建方法和应用
CA3187128A1 (fr) * 2020-08-12 2022-02-17 Andrew A. Dahl Utilisation de microbes variovorax comme traitement de substitution pour la coccidiose

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149604A (en) 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8465755B2 (en) * 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
WO2010045620A1 (fr) * 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Bactérie recombinante pouvant éliciter une réponse immunitaire contre le streptococcus pneumoniae
WO2011150421A2 (fr) * 2010-05-28 2011-12-01 The Arizona Board Of Regents For And On Behalf Of Arizona State University Bactérie recombinante permettant de diminuer la croissance tumorale
WO2012087483A1 (fr) * 2010-11-24 2012-06-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University Bactérie recombinante renfermant un système toxine-antitoxine
EP2925346A1 (fr) 2012-11-30 2015-10-07 Universite d'Auvergne Clermont I Utilisation de microorganismes pour diminuer le taux de triméthylamine dans une cavité du corps humain, notamment pour le traitement de la triméthylaminurie ou d'une vaginose bactérienne et la prévention des maladies cardiovasculaires
WO2015118541A1 (fr) * 2014-02-05 2015-08-13 Gavish-Galilee Bio Applications Ltd Système génétique pour générer des bactéries inactivées ou atténuées de manière conditionnelle
WO2018018041A1 (fr) 2016-07-22 2018-01-25 University Of Florida Research Foundation, Incorporated Conception d'un vaccin anti-zikv qui n'a pas de réaction croisées avec la dengue.
CA3050724A1 (fr) * 2017-01-23 2018-07-26 University Of Florida Research Foundation, Incorporated Induction d'immunite protectrice contre des antigenes
CN111182920B (zh) 2017-08-04 2023-09-12 佛罗里达大学研究基金公司 针对抗原的保护性免疫的诱导

Also Published As

Publication number Publication date
MX2019008645A (es) 2019-12-02
US20190382717A1 (en) 2019-12-19
US20210284955A1 (en) 2021-09-16
RU2019126659A (ru) 2021-02-24
WO2018136938A8 (fr) 2019-09-12
EP3571288A4 (fr) 2020-12-02
RU2019126659A3 (fr) 2021-06-01
CA3050724A1 (fr) 2018-07-26
US10988729B2 (en) 2021-04-27
US11788056B2 (en) 2023-10-17
JP2020505036A (ja) 2020-02-20
BR112019015140A2 (pt) 2020-04-14
CN110462020B (zh) 2023-10-24
WO2018136938A1 (fr) 2018-07-26
EP3571288A1 (fr) 2019-11-27
JP7121016B2 (ja) 2022-08-17
CN110462020A (zh) 2019-11-15
AU2018210554A1 (en) 2019-08-22
AU2018210554B2 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
MA47317A (fr) Induction d'immunité protectrice contre des antigènes
MA49771A (fr) Induction d'une immunité protectrice contre des antigènes
MA49715A (fr) Oligomères et conjugués d'oligomères
EP3303083A4 (fr) Réduction des risques d'itinéraire
EP3526328A4 (fr) Polythérapie pour l'inhibition de c3
EP3419674A4 (fr) Immunothérapie de ciblage de l'amyloïdose
EP3328363A4 (fr) Compositions et méthodes d'immunomodulation
AP2016009479A0 (en) Transgenic maize event mon 87419 and methods of use thereof
EP3448417A4 (fr) Conjugués dimères d'insuline-incrétine
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
EP3478315A4 (fr) Méthodes et compositions d'inhibition du récepteur immunitaire inhibiteur
EP3533253A4 (fr) Régulation d'encombrement 5g
SG11201702059QA (en) "an article of furniture"
EP3415524A4 (fr) INHIBITEUR D'EXPRESSION DE L'a-SYNUCLÉINE
BE1022355A1 (fr) Nouvelles méthodes d'induction d'une réponse immunitaire
ITUB20153017A1 (it) Dispositivo per l'avvolgimento di prodotti
EP3444345A4 (fr) Dérivé d'arnmicro-143
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
EP3781195A4 (fr) Antigènes vaccinaux chimériques contre l'anaplasmose
EP3697947A4 (fr) Prise en compte d'effets d'ajustement induit
EP3387469A4 (fr) Détermination d'électrofaciès
ES1109830Y (es) " senalador de prendas"
IL248728A0 (en) Composition and invention for the induction of tumor immunity
EP3381460A4 (fr) Inhibiteur de l'angiogenèse
EP3437652A4 (fr) Agent d'induction d'immunité